Sunovion advances schizophrenia drug for bipolar disorder

Sunovion Pharmaceuticals Inc. said the U.S. Food and Drug Administration has accepted its applications to expand the indication of its schizophrenia drug, Latuda to be used as a treatment for bipolar disorder. One application requests approval for Latuda to be used in combination with other drugs, and the other requests an approval to be prescribed as a bipolar treatment on its own.